Yahoo! FinanceHome - Yahoo! - Help

Market Guide

[ Stock Screener | Company & Fund Index | Financial Glossary ]

Profile - AtheroGenics, Inc. (NasdaqNM:AGIX)
As of 31-Aug-2001
Enter symbol:
symbol lookup

 
More Info: Quote | Chart | News | Profile | Research | SEC | Msgs | Insider | Financials
Location
8995 Westside Parkway
Alpharetta, GA 30004
Phone: (678) 336-2500
Fax: (678) 336-2501
Email: investor@atherogenics.com
Employees (last reported count): 70
Financial Links
 ·Top Institutional Holders
 ·Top Mutual Fund Holders
 ·Analyst Upgrade/Downgrade History
 ·Historical Quote Data
 ·Raw SEC Filings at sec.gov
Competitors:
 ·Sector: Healthcare
 ·Industry: Biotechnology & Drugs
Company Websites
 ·Home Page
 ·Investor Relations
 ·Yahoo! Category

 ·Search Yahoo! for related links...

Ownership
·Insider and 5%+ Owners: 51%
·Over the last 6 months:
 · 9 insider sells; 2.18M shares
  (13.3% of insider shares)
·Institutional: 38% (78% of float)
(40 institutions)
·Net Inst. Buying: 4.39M shares (+29.25%)
(prior quarter to latest quarter)
More From Market Guide
 ·Highlights
 ·Performance
 ·Ratio Comparisons
Business Summary
AtheroGenics, Inc. is a pharmaceutical company focused on the discovery, development and commercialization of novel drugs for the treatment of chronic inflammatory diseases, such as atherosclerosis, rheumatoid arthritis and asthma. The Company designed its lead product candidate, AGI-1067, to benefit patients with coronary artery disease, which is atherosclerosis of the blood vessels of the heart. The Company has developed a proprietary vascular-protectant (v-protectant) technology platform to discover drugs for the treatment of chronic inflammation. AGI-1067 is the Company's v-protectant candidate that is most advanced in clinical development. The Company has identified other potential v-protectant product candidates to treat asthma, exacerbation of rheumatologic diseases and solid organ transplant rejection. The Company is evaluating these v-protectant product candidates to choose lead product candidates for clinical development.
More from Market Guide: Expanded Business Description

Financial Summary
AtheroGenics is a pharmaceutical company focused on discovery, development and commercialization of novel drugs for the treatment of chronic inflammatory diseases. For the six months ended 6/30/01, revenues fell 54% to $1.9 million. Net loss increased 9% to $7.1 million. Revenues reflect lower billings to the Phase II clinical study. Higher net loss reflects increased research and development expenses associated with AGIX-4207 clinical trials and other pre-clinical costs.
More from Market Guide: Significant Developments

Officers[Insider Trade Data]
FY2000 Compensation
PayExer

Michael Henos, 52
Chairman
--  --  
Russell Medford, M.D., Ph.D., 46
Pres, CEO, Director
$392K--  
Mark Colonnese, 46
CFO, VP of Fin. and Admin., Assistant Sec.
270K$342K
Mitchell Glass, M.D., 49
Sr. VP, Strategic Drug Devel.
258K398K
William Scott, Ph.D., 60
VP, Director
--  --  
Dollar amounts are as of 31-Dec-2000 and compensation values are for the fiscal year ending on that date; "Pay" is salary, bonuses, etc.; "Exer" is the value of options excercised during the fiscal year.
More from Market Guide on Officers & Directors:
Expanded List, Bios, Compensation, Options
Statistics at a Glance -- NasdaqNM:AGIXAs of 31-Aug-2001
Price and Volume
52-Week Low
on 28-Dec-2000
$4.375
Recent Price$6.00 
52-Week High
on 5-Sep-2000
$11.50 
Daily Volume (3-month avg)133.5K
Daily Volume (10-day avg)87.0K
Stock Performance
[one-year price graph]
big chart [1d | 5d | 3m | 6m | 1y | 2y]
52-Week Change-44.2%
52-Week Change
relative to S&P500
-25.1%
Share-Related Items
Market Capitalization$166.7M
Shares Outstanding27.8M
Float13.6M
Dividends & Splits
Annual Dividendnone 
Last Splitnone 
Per-Share Data
Book Value (mrq)$2.42 
Earnings (ttm)-$0.73 
Earnings (mrq)-$0.16 
Sales (ttm)$0.28 
Cash (mrq)$2.46 
Valuation Ratios
Price/Book (mrq)2.48 
Price/EarningsN/A 
Price/Sales (ttm)21.77 
Income Statements
Sales (ttm)$5.92M
EBITDA (ttm)-$12.3M
Income available to common (ttm)-$14.5M
Profitability
Profit MarginN/A 
Operating MarginN/A 
Fiscal Year
Fiscal Year EndsDec 31
Most recent quarter30-June-2001
Management Effectiveness
Return on Assets (ttm)-28.47%
Return on Equity (ttm)-36.73%
Financial Strength
Current Ratio (mrq)17.05 
Debt/Equity (mrq)0.00 
Total Cash (mrq)$68.1M
Short Interest
As of 8-Aug-2001
Shares Short19.0K
Percent of Float0.1%
Shares Short
(Prior Month)
7,000 
Short Ratio0.17 
Daily Volume109.0K
See Profile Help for a description of each item above;   K = thousands;   M = millions;   mrq = most-recent quarter;   ttm = trailing twelve months;   (as of 30-June-2001)

Market Guide offers more in-depth Company Research, Stock Screening, and Hottest Stocks and Industries on over 10,000 U.S. Equities.


Copyright © 2001 Yahoo! Inc. All Rights Reserved. Privacy Policy - Terms of Service
Company information Copyright Market Guide. Historical chart data and daily updates provided by Commodity Systems, Inc. (CSI). Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither Yahoo nor any of its data or content providers (such as Market Guide, CSI, etc.) shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon.